Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Yasuhiko Tabata currently has 1 pending office action within the Biotechnology & Pharmaceuticals technology area. This 1 pending office action is being reviewed by 1 distinct examiner, JAGAMYA NMN VIJAYARAGHAVAN. The matter is situated within 1 distinct art unit, reflecting a singular administrative and technical classification for the current filing.
JAGAMYA NMN VIJAYARAGHAVAN is the busiest examiner for this entity, currently managing 1 pending office action. Since there is only 1 distinct examiner and 1 distinct art unit, the prosecution of this biotechnological technology is highly centralized. The outcome of the 1 pending office action depends entirely on the interactions between the applicant and this single examiner within the designated art unit.
Practitioners should note that the lack of multiple pending actions prevents any comparison of examiner behavior or art unit standards within this portfolio. The prosecution strategy is focused on the 1 pending office action handled by JAGAMYA NMN VIJAYARAGHAVAN. This concentration means that the current presence in the biotechnology patent landscape is defined by this single active matter.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| VIJAYARAGHAVAN, JAGAMYA NMN | 1 | 61.0% | +51.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18026482 | CELL-SUPPORTING BODY, MANUFACTURING METHOD THEREFOR, CELL CULTURING METHOD, AND CELL STRUCTURE | VIJAYARAGHAVAN, JAGAMYA NMN | 24d overdue |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18026482 | CELL-SUPPORTING BODY, MANUFACTURING METHOD THEREFOR, CELL CULTURING METHOD, AND CELL STRUCTURE | VIJAYARAGHAVAN, JAGAMYA NMN | 24d overdue |
| Art Unit | Apps |
|---|---|
| 1633 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18026482 | CELL-SUPPORTING BODY, MANUFACTURING METHOD THEREFOR, CELL CULTURING METHOD, AND CELL STRUCTURE | VIJAYARAGHAVAN, JAGAMYA NMN | 1633 | §102§103 | Final Rejection | 24d overdue | Pending | Mar 15, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialYasuhiko Tabata has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Jagamya Nmn Vijayaraghavan has the most, with 1 of Yasuhiko Tabata's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
